Skip to main content
Terug
RYTM logo

Rhythm Pharmaceuticals, Inc.

Datakwaliteit: 100%
RYTM
NASDAQ Healthcare Biotechnology
€ 82,59
▼ € 2,06 (-2,43%)
Marktkapitalisatie: 5,64B
Dagbereik
€ 80,70 € 83,75
52-Weeksbereik
€ 45,91 € 122,20
Volume
771.417
50D / 200D Gem.
€ 99,01 / € 96,18
Vorige Slotkoers
€ 84,65

Koershistorie

Financiële Trends

Sectorvergelijking

vs Healthcare sector mediaan (627 peers)

Metriek Aandeel Sector Mediaan
P/E -28,7 0,3
P/B 40,6 2,9
ROE % -129,5 3,7
Net Margin % -103,6 3,8
Rev Growth 5Y % 178,5 10,0
D/E 1,8 0,2

Koersdoel Analisten

Hold
€ 140,18 +69.7%
Low: € 125,00 High: € 157,00
Forward WPA
-€ 3,08
Omzet Sch.
290 M

Winstschattingen

Periode WPA Sch. Omzet Sch. Analisten
FY2030 € 12,09
€ 8,29 – € 14,94
1,9 B 3
FY2029 € 7,49
€ 5,13 – € 9,25
1,4 B 3
FY2028 € 3,08
€ 0,10 – € 5,89
900 M 9

Belangrijkste Punten

Revenue grew 178,51% annually over 5 years — strong growth
Negative free cash flow of -116,63M
Revenue growth is decelerating — 1Y growth trails 5Y average by 132,68%
Capital efficient — spends only 0,50% of revenue on capex

Groei

Revenue Growth (5Y)
178,51%
Revenue (1Y)45,83%
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Kwaliteit

Return on Equity
-129,46%
ROIC-37,35%
Net Margin-103,57%
Op. Margin-101,19%

Veiligheid

Debt / Equity
1,77
Current Ratio4,41
Interest Coverage-9,33

Waardering

P/E Ratio
-28,69
P/B Ratio40,55
EV/EBITDAN/A
Dividend Yield0,00%

All Fundamental Metrics

Growth
Revenue Growth (1Y) 45,83% Revenue Growth (3Y) 56,55%
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) 178,51% Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 189,76M Net Income (TTM) -196,54M
ROE -129,46% ROA -40,84%
Gross Margin 89,73% Operating Margin -101,19%
Net Margin -103,57% Free Cash Flow (TTM) -116,63M
ROIC -37,35% FCF Growth (3Y) N/A
Safety
Debt / Equity 1,77 Current Ratio 4,41
Interest Coverage -9,33 Dividend Yield 0,00%
Valuation
P/E Ratio -28,69 P/B Ratio 40,55
P/S Ratio 29,72 PEG Ratio 1,25
EV/EBITDA N/A Dividend Yield 0,00%
Market Cap 5,64B Enterprise Value 5,83B

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 189,76M 130,13M 77,43M 23,64M 3,15M
Net Income -196,54M -260,60M -184,68M -181,12M -69,61M
EPS (Diluted) -3,11 -4,34 -3,20 -3,51 -1,37
Gross Profit 170,27M 116,76M 68,13M 21,51M 2,56M
Operating Income -192,02M -265,50M -184,36M -179,16M -170,06M

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 481,19M 392,27M 332,75M 382,48M 329,52M
Total Liabilities 342,13M 227,72M 162,99M 118,22M 45,37M
Shareholders' Equity 139,07M 164,55M 169,76M 264,26M 284,15M
Total Debt 246,47M 3,94M 1,26M 1,94M 2,55M
Cash & Equivalents 54,30M 89,14M 60,08M 127,68M 59,25M
Current Assets 466,92M 374,20M 308,27M 354,24M 308,39M
Current Liabilities 105,94M 115,52M 55,20M 39,81M 43,43M

Strategiescores

This stock passed the criteria for 1 strategy

Score = fit strength (0–100)
Rank = position among all matches
Custom Full Throttle
#9 of 146
74

Recente Activiteit

Ingestapt Full Throttle
Mar 24, 2026